A study by CUNY SPH researchers, in close partnership with colleagues from Weill Cornell Medicine and NYU School of Medicine, suggests that treating people who inject drugs for hepatitis C infection using the accessible care model, which is characterized by low-threshold, nonstigmatizing care co-located in a syringe service program, is more effective than the usual care model, in which patients are referred to local clinicians.